Needham & Company LLC Reiterates "Buy" Rating for Boston Scientific (NYSE:BSX)

2026-03-24 05:33:00

Needham & Company LLC has reiterated a “Buy” rating for Boston Scientific (NYSE:BSX) with a $97 price target, indicating a potential 38.5% upside. This comes despite recent negative news regarding an expanded pacemaker recall and allegations of prior management knowledge of battery issues, which have led to lawsuits and increased regulatory scrutiny. Several other analysts have also maintained “buy” or “outperform” ratings, though some have lowered price targets, reflecting a mixed outlook amidst both strong quarterly earnings and significant legal/reputational challenges.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes